Moderna, Inc. 4

Moderna CEO Stephane Bancel exercised expiring stock options and sold 499,246 Moderna (MRNA) shares to cover costs under a 10b5-1 plan while increasing his net direct holdings.

On August 5–6, 2026, Moderna CEO Stephane Bancel exercised in full two expiring stock option awards for a total of 752,322 shares of common stock at a $19.15 strike price and, in connection with a Rule 10b5-1 cashless exercise-and-hold plan adopted on May 4, 2026, sold 499,246 shares at weighted average prices around $56–59 solely to cover the option exercise cost, taxes, and related fees, retaining the remaining newly acquired shares. Following these transactions, he reported direct ownership of 6,370,835 Moderna common shares, with additional indirect holdings through Boston Biotech Ventures (9,210,686 shares) and OCHA LLC (6,564,880 shares), which he disclaims as beneficial except to the extent of his pecuniary interest.

Filing Facts

CIK

1682852

Ticker

MRNA

Form

4

Source Type

fda

Accession

0001682852-26-000153

Alert Tier

6